Blog

DEEP RESEARCH · KOREA BIOTECH 2026

A Quick Look at Korean Biotech in 2026: When Dreams Need to Become Reality

A beginner-friendly map of obesity drugs, ADCs, SC formulations, and technology-export companies

Date: 2025-11-26 · biotech/sector primer view · Naver Blog

Investment decisions are your own responsibility. This material is research, not a recommendation to buy or sell.

0. Bottom line first

When studying biotech, I want to start with Korean companies, then look at China as a competitor and global biotech as the upstream demand side. The source's core view is that 2025-2026 may be the period when Korean biotech companies move beyond “we have the technology” and prove themselves through FDA approvals, technology exports, and real revenue.

2026 biotech-healthcare watchpointsMoving from potential to measurable results
ObesityFrom weekly injections to monthly or oral options
ADCAntibody-drug conjugates targeting cancer cells
SC formulationTurning IV drugs into at-home injections
Tech exportsGlobal pharma contracts and royalties
The key question is not terminology, but who owns which technology and which global pharma partner is involved

1. Why biotech now?

Official fact: The source frames 2026 as a year when overall Korean economic growth may be slow and traditional leaders such as semiconductors and autos may also decelerate, while biotech-healthcare still carries meaningful growth expectations.

Interpretation: Korean biotech companies have long shown potential. In 2025-2026, the market may ask them to prove it through FDA approvals, global pharma licensing deals, drug sales, and royalties.

2. Core trend: more convenient, more precise

2.1 Obesity drugs: from weekly injections to monthly or oral dosing

Current obesity injections such as Wegovy and Zepbound need to be taken every week. The source argues that monthly injections or pills swallowed with water could be highly attractive for obesity patients who need lifelong management.

Peptron

Smart depot

A technology designed to release drug effects slowly over a month. The source says global pharma company Lilly is interested and testing the technology.

D&D Pharmatech

OralLink

A technology intended to turn injectable peptide ingredients into oral drugs. The source highlights convenience versus injections.

2.2 Cancer drugs: ADCs as guided missiles

Older cancer drugs often attacked normal cells too, causing side effects such as hair loss and vomiting. The source compares ADCs to guided missiles: a radar-like antibody guides the drug payload to cancer cells.

ADC analogyAntibody-drug conjugate
AntibodyRadar that finds the cancer-cell target
LinkerConnector between antibody and payload
PayloadThe drug delivered to the cancer cell
EffectHigher precision and potentially fewer side effects
The source describes LigaChem Biosciences' linker technology as world-class

3. Beginner glossary for biotech terms

TermKorean nameSimple analogy and explanation
ModalityModalityThe form of the treatment tool. The source compares pills to rifles, antibody therapies to tanks, and gene therapies to nuclear weapons.
ADCAntibody-drug conjugateA guided missile. The antibody finds cancer cells, while the drug acts as the explosive payload.
TPDTargeted protein degradationA cell-cleaner call button. It tags disease-causing proteins so the body's cleanup system breaks them down.
CDMOContract development and manufacturingThe TSMC of biotech, or a bakery. A pharma company provides the recipe, and the CDMO makes the drug. Samsung Biologics is given as the representative example.
SC formulationSubcutaneous injectionAn at-home injection. It changes hours-long IV administration in a hospital into a roughly five-minute injection into the abdomen or thigh; Alteogen is mentioned as a related company.

4. Companies to watch in 2026 and investment points

Alteogen

IV to SC

Owns enzyme technology that converts IV administration into SC injections. The source says Keytruda uses Alteogen's technology and that a royalty structure can begin taking shape in 2025-2026.

Peptron

Long-acting obesity treatment

Aims to reduce weekly obesity injections to monthly dosing. The technology-evaluation agreement with Lilly is presented as the key watchpoint before any full contract.

LigaChem Bio

ADC technology exports

The source expects ongoing ADC technology exports to global pharma companies to support technology-fee inflows and earnings improvement.

ABL Bio

Bispecific antibodies

Has bispecific-antibody technology that can bind cancer cells with one arm and immune cells with the other. The source also notes its brain-disease technology export to Sanofi.

5. How to think about investing

  1. Look for companies with numbers: Prefer companies that have already received upfront payments from technology exports or are close to FDA approval, rather than companies supported only by expectations. The source examples are Alteogen and LigaChem Bio.
  2. Follow the trend: Global capital is moving toward obesity and ADC. The source highlights related names such as Peptron and D&D Pharmatech.
  3. Check cash: Biotech companies spend heavily on R&D. If cash is low, there is risk of asking shareholders for money through paid-in capital increases. Companies with ample cash or incoming technology fees are viewed as safer.

Sources

Naver original